Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus
Journal Title: Journal of Diabetes and Obesity - Year 2016, Vol 4, Issue 1
Abstract
Background: The maximum permissible dose of liraglutide, a GLP-1 receptor agonist, under the Japanese Heath Insurance system is 0.9 mg/day. We determined the effects of adding metformin to liraglutide therapy in Japanese patients with type 2 diabetes. Material and Methods: This observational retrospective study included 47 patients with type 2 diabetes who were treated with liraglutide alone or in combination with sulfonylureas. Metformin was added at a dose ranging from 250 to 500 mg/day based on inadequate glycemic control. Liraglutide and metformin doses were converted from mg/day to mg/kg body weight/day before analysis of the correlation between the dose and changes in glycated hemoglobin (HbA1c) and body mass index (BMI). Results: Both HbA1c and BMI decreased significantly after 24 weeks of the combination treatment. Mild gastrointestinal adverse events were reported by 21% of the patients. Only the dose of metformin, but not that of liraglutide, expressed in mg/kg body weight was correlated significantly with decrease in HbA1c and BMI. Conclusions: The addition of metformin to the maximum permissible dose of liraglutide helps secure glycemic control and reduce BMI in Japanese patients with type 2 diabetes who exhibit inadequate response to liraglutide.
Authors and Affiliations
Masao Toyoda
Keywords
Related Articles
- EP ID EP417851
- DOI 10.15436/2376-0494.17.1300
- Views 105
- Downloads 0
Estimated Stearoyl-CoA-desaturase (SCD)-1 and Elongase of Very Long Chain Fatty Acids (Elovl) 6 Activities From Serum Fatty Acids Are Reciprocally Associated with Visceral Fat Area in Type 2 Diabetic Patients
Introduction Abdominal visceral fat accumulation can cause insulin resistance in type 2 diabetic patients We investigated the association between serum fatty acid levels and the visceral fat area VFA Materials and...
Herbal Anti-Hyperglycemic Compound Improves Glycemic Control and Insulin Sensitivity in Diabetic Rats
Objective: To study the effect of HPLC purified herbal anti-hyperglycemic active compound (FIIc) isolated from the fruit pulp of Eugenia jambolana in diabetic rats. Methods: 24 male wistar rats were taken and diabetes wa...
Effect of Haematogenous oxidation therapy with Ultraviolet-C irridation in an alloxan-induced diabetes and a Poloxamer 407-induced Hyperlipidemia in rabbits
Background Recently diabetes and hyperlipidemia HL considered a major source of mortality Chemical treatments could minimize the symptoms but still the disease exists Previously Ultraviolet was usedfor treatment...
Determining the Development of Insulin Resistance in Older Adults of the NuAge cohort Using Trajectory Modeling of the Homeostatic Model Assessment of Insulin Resistance Score
Background: Age-associated body composition changes increase the risk of developing insulin resistance. Identifying these subjects in epidemiological studies is challenging. Objective: Identify insulin-resistant subjects...
Occurrence of Left Ventricular Hypertrophy in Subjects with Metabolic Syndrome: Role of Adiponectin
This study was designed to evaluate the role of total plasma adiponectin ADPN on the occurrence of left ventricular hypertrophy in subjects with metabolic syndrome MetS compared to a control group without MetS The m...